Flow cytometric detection of CD79a expression in T-cell acute lymphoblastic leukemias.

We evaluated the lineage specificity of CD79a in acute leukemias using 3-color flow cytometry in 58 consecutive cases. A panel of cell-surface antigens, including myeloid-associated markers, B-cell-associated markers, and T-cell-associated markers, was used. All cases of acute myeloid leukemia were CD79a-, whereas all cases of B-lineage acute lymphoblastic leukemia (ALL) were CD79a+. Three of 8 cases of T-cell ALL showed variable CD79a expression, indicating the presence of a blast subset expressing a relatively high level of CD79a. We investigated the clinical and pathologic characteristics of these 3 cases. All 3 cases had L1 or L2 morphology and expressed surface CD3. None of the other B-cell-associated markers were positive, although 1 case expressed CD13 and CD33. Uncommon random karyotypic abnormalities were identified in all 3 cases. Molecular studies demonstrated monoclonal gene rearrangement of T-cell receptor gamma in 2 of 3 cases. All 3 patients were 18 years old or younger; 1 patient did not enter remission, and 1 had disease relapse in 8 months. Our findings provide further support for the existence of a subset of T-cell ALL coexpressing CD3 and CD79a. Further study of the clinical and biologic significance of this subset may be warranted.

[1]  F. Behm,et al.  T-cell acute lymphoblastic leukemia with t(11;14) in children. , 1992, Leukemia & lymphoma.

[2]  F. Behm,et al.  Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. , 1990, Blood.

[3]  E. Jaffe,et al.  CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples. , 1995, Blood.

[4]  H. Ha,et al.  Molecular cloning and expression pattern of a human gene homologous to the murine mb-1 gene. , 1992, Journal of immunology.

[5]  M. Borowitz,et al.  Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. , 1993, American journal of clinical pathology.

[6]  M. Slovak,et al.  The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities. , 1998, American journal of clinical pathology.

[7]  H. Müller-Hermelink,et al.  Gene rearrangements in T‐cell lymphoblastic lymphoma , 1999, The Journal of pathology.

[8]  D. Mason,et al.  Antigen Receptors on T and B Lymphocytes: Parallels in Organization and Function , 1993, Immunological reviews.

[9]  H. Müller-Hermelink,et al.  Co‐expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma , 1998, The Journal of pathology.

[10]  Jonathan J. Shuster,et al.  Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study , 1990 .

[11]  P. Gaulard,et al.  Discordant expression of immunoglobulin and its associated molecule mb-1/CD79a is frequently found in mediastinal large B cell lymphomas. , 1995, The American journal of pathology.

[12]  N. Heerema,et al.  Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. , 1998, Blood.

[13]  Noel R. Rose,et al.  Manual of clinical laboratory immunology , 2002 .

[14]  N. Heerema,et al.  Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children's Cancer Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. V. van Dongen,et al.  The IgM-associated protein mb-1 as a marker of normal and neoplastic B cells. , 1991, Journal of immunology.

[16]  M. Slovak,et al.  Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. , 1999, American journal of clinical pathology.

[17]  Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny. , 1998 .

[18]  D. Mason,et al.  The membrane IgM-associated heterodimer on human B cells is a newly defined B cell antigen that contains the protein product of the mb-1 gene. , 1991, Journal of immunology.

[19]  S. Pileri,et al.  Acute leukaemia immunophenotyping in bone‐marrow routine sections , 1999, British journal of haematology.

[20]  C. Pui,et al.  Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Korkolopoulou,et al.  The expression of the B‐cell marker mb‐1 (CD79a) in Hodgkin's disease , 1994, Histopathology.

[22]  F. Melchers,et al.  B lymphocyte lineage‐restricted expression of mb‐1, a gene with CD3‐like structural properties. , 1988, The EMBO journal.

[23]  Iscn International System for Human Cytogenetic Nomenclature , 1978 .

[24]  J. Sloane,et al.  The rapid detection of clonal T-cell proliferations in patients with lymphoid disorders. , 1991, The American journal of pathology.

[25]  J. Cambier,et al.  Membrane immunoglobulin and its accomplices: new lessons from an old receptor 1 , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.